Remimazolam Besilate

苯磺酸瑞马唑仑

Report date: 2026/03/22 20:00:17
NME

Base Information

Drug NameRemimazolam Besilate
Drug Alias Name苯磺酸瑞米唑仑Remimazolam besylateremimazolam瑞马唑仑Remazolam +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsSedationPharmaceutical aidsPain, Postoperative +[6] 
Global Approved IndicationsSedationAnesthesia
Approved Indications in ChinaSedation
Original Approved Country/TerritoryJapan
Original Approved Date2020/01/23
Country/TerritoryUnited StatesRussian FederationGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPaion Pharma
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPaion Deutschland GmbhMundipharma KkEagle Pharmaceuticals Inc +[5] 
Inactive CompaniesPaion Uk LtdR-Pharm JscOno Pharmaceutical Co Ltd +[4] 
Active IndicationsSedationAnesthesia
Inactive IndicationsPharmaceutical aidsPain, PostoperativeBronchial Diseases +[4] 

Other Information

ATC CodeN05CD14
Related LinksWikipediaDrugBankKEGG